BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80. [PMID: 31660640 DOI: 10.1111/apt.15555] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 2023. [PMID: 36635577 DOI: 10.1007/s00296-022-05270-6] [Reference Citation Analysis]
2 Deng LR, Han Q, Zou M, Chen FJ, Huang CY, Zhong YM, Wu QY, Tomlinson B, Li YH. Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking. Chin Med 2022;17:132. [PMID: 36434688 DOI: 10.1186/s13020-022-00684-7] [Reference Citation Analysis]
3 Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, Amiot A, Bouguen G. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 2022. [PMID: 36401585 DOI: 10.1111/apt.17305] [Reference Citation Analysis]
4 Kakiuchi T, Yoshiura M. Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report. Medicine (Baltimore) 2022;101:e31757. [PMID: 36397383 DOI: 10.1097/MD.0000000000031757] [Reference Citation Analysis]
5 Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis 2022:izac222. [PMID: 36242764 DOI: 10.1093/ibd/izac222] [Reference Citation Analysis]
6 Cohen NA, Steinberg JM, Silfen A, Traboulsi C, Rodriguez TG, Singer JM, Patel S, Cohen RD, Dalal SR, Sakuraba A, Pekow J, Micic D, Rubin DT. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci 2022. [PMID: 36242686 DOI: 10.1007/s10620-022-07716-0] [Reference Citation Analysis]
7 Irving PM, Leung Y, Dubinsky MC. Review article: guide to tofacitinib dosing in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:1131-45. [PMID: 35993338 DOI: 10.1111/apt.17185] [Reference Citation Analysis]
8 Han Q, Deng LR, Zou M, Tang HZ, Huang CY, Chen FJ, Tomlinson B, Li YH. Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota. Phytomedicine 2022;106:154416. [PMID: 36037770 DOI: 10.1016/j.phymed.2022.154416] [Reference Citation Analysis]
9 Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:1821-1830.e3. [PMID: 33127596 DOI: 10.1016/j.cgh.2020.10.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
10 Maqsood MH, Weber BN, Haberman RH, Lo Sicco KI, Bangalore S, Garshick MS. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials. ACR Open Rheumatology 2022. [DOI: 10.1002/acr2.11479] [Reference Citation Analysis]
11 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
12 Gopalakrishnan S, Hansen MD, Skovdahl HK, Roseth IA, van Beelen Granlund A, Østvik AE, Bakke I, Sandvik AK, Bruland T. Tofacitinib Downregulates TNF and Poly(I:C)-Dependent MHC-II Expression in the Colonic Epithelium. Front Immunol 2022;13:882277. [PMID: 35655783 DOI: 10.3389/fimmu.2022.882277] [Reference Citation Analysis]
13 . Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). Z Gastroenterol 2022;60:1047-50. [DOI: 10.1055/a-1851-7777] [Reference Citation Analysis]
14 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2022;28:32-40. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
18 Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:116-125.e5. [PMID: 33039585 DOI: 10.1016/j.cgh.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
19 Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
20 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2022;16:835-44. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:2010-22. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1288-97. [PMID: 33405424 DOI: 10.1097/MEG.0000000000002028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
24 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1592-1601.e3. [PMID: 32629130 DOI: 10.1016/j.cgh.2020.06.050] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 19.5] [Reference Citation Analysis]
26 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, Charde S, Basit AW. 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. Biomedicines 2021;9:578. [PMID: 34065300 DOI: 10.3390/biomedicines9050578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lucaciu L, Constantine-cooke N, Plevris N, Siakavellas S, Derikx L, Jones G, Lees C. Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis.. [DOI: 10.1101/2021.04.27.21256170] [Reference Citation Analysis]
29 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis 2021;15:1130-41. [PMID: 33290538 DOI: 10.1093/ecco-jcc/jjaa249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
31 Heo Y. Tofacitinib in ulcerative colitis: a profile of its use. Drugs Ther Perspect 2020;36:553-563. [DOI: 10.1007/s40267-020-00789-9] [Reference Citation Analysis]
32 Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. J Crohns Colitis 2020;14:S737-45. [PMID: 31879750 DOI: 10.1093/ecco-jcc/jjz202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
33 Agrawal M, Kim ES, Colombel JF. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. J Crohns Colitis 2020;14:S755-60. [PMID: 32006031 DOI: 10.1093/ecco-jcc/jjaa017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
34 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
35 Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance. Frontline Gastroenterol 2021;12:133-6. [PMID: 33613945 DOI: 10.1136/flgastro-2020-101502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
37 Peng C, Jiexin L, Yue W, Benhong Z. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Aliment Pharmacol Ther 2020;51:996-7. [PMID: 32338779 DOI: 10.1111/apt.15674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Aliment Pharmacol Ther 2020;51:997-8. [PMID: 32338784 DOI: 10.1111/apt.15716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880-8. [PMID: 32237087 DOI: 10.1111/apt.15689] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
40 Amiot A. Letter: new insights on tofacitinib dose de-escalation. Aliment Pharmacol Ther 2020;51:578. [PMID: 32048759 DOI: 10.1111/apt.15638] [Reference Citation Analysis]